Back to All Cases

Legal Report written by the German lawyer Beate Bahner, outlining the many violations under German & EU Law of the Covid Inoculation program. (Dated Dec 27, 2021)

• Section 1 : is the full original document (in German)

• Section 2 : is a ‘Working English’ translation made by Corona Cases of item “9. Summary” of lawyer Bahner’s document

(i.e. it is not an ‘official translation’ authorized for legal purposes but only intended as an aid to understanding of the main content of the German summary.)

• Section 3 : is a Video in which she warns of the Criminal Consequences of participating in the inoculation program (with English Subtitles).

1

Click the “View Fullscreen” button below to get full functionality in fullscreen.

2

9. Summary

1. A substance may only be used for the manufacture of a medicinal product if the intended use is either described in a monograph in accordance with the pharmacopoeia in a monograph, or extensive additional studies, including toxicity studies and clinical studies are submitted for the new new excipients. 

2. The sense and purpose of all German and European pharmaceutical regulations is the protection of people through the quality, safety and efficacy of medicinal products.

3. EMA [the European Medicines Agency] has imposed special conditions on BioNTech – particularly with regard to the two lipid nanoparticles, ALC 0315 and ALC 0159 in particular, as these are novel adjuvants for the Comirnaty vaccine and used for the first time on humans and in a novel way.

4. The corresponding special conditions of the EMA (specific obligations SO2, SO4, SO5) for these novel adjuvants had to be fulfilled by Biontech by July 2021.

5. Both the EMA report on the extension of the conditional marketing authorization in October 2021 as well as the safety data sheet of Pfizer for Comirnaty dated 7.12.2021 show that these conditions have not been fulfilled and that the required documentation is not available. It says: “No data available”. 

6. This is a violation of the principles of good manufacturing practice and thus also a a violation of the recognized pharmaceutical rules in the sense of § 8 para. 1 no. 1 AMG. According to this, it is forbidden to bring medicinal products into the market such that “by deviation from the recognized pharmaceutical rules, their quality is not insignificantly reduced”.

7. The quality is already reduced by the fact alone that two essential ingredients contained in Comirnaty are not intended for use in or on humans and are therefore considered “novel excipients” for which special documents and evidence must be provided.

8. In addition, lipid-related impurities in the vaccine are already documented in EMA’s registration dossier. Impurities of the vaccine are documented. These impurities are likely to increase in the light of further information on the reduction in filtration processes of the adjuvant nanolipid ALC-0315, these impurities may have even increased. With the reduction of the filtering processes, the marketing authorization holder would also violate S02, SO4 and SO5 of EMA in the marketing authorization notice.

9. Finally, according to the safety reports of the Paul Ehrlich Institute, the vaccine shows an alarming number of harmful effects that far beyond what is “justifiable” according to medical science.

10. Due to this fact, there is furthermore a violation of § 5 para. 1 AMG namely, a violation of the prohibition of the marketing and use of questionable medicinal products. Thus, not only the manufacturers but also the vaccinating physicians, as well as all persons responsible for a vaccination with Comirnaty are subject to the regulations of the Medicinal Products Act.

11. Violations of § 8 AMG and § 5 AMG are classified as criminal offenses according to § 95 para. 1 no. 1 and no. 3a and are punishable by up to 3 years’ imprisonment. Negligent commission is also punishable, § 95 para. 4 AMG.

12. A particularly serious case of this offense with imprisonment of up to 10 years if another person is exposed to the risk of death or serious injury to body or health, § 95 (3) No. 2 AMG. In this case is the manufacture, distribution and use of the vaccine Comirnaty contrary to the prohibitions of §§ 5 and 8 AMG. is intentionally realized.

13. Furthermore, vaccination may not be carried out in the case of allergies to a component of the vaccine. Therefore, all persons to be vaccinated must be tested in advance for a possible allergy to one of the components in order to exclude any contraindication to the vaccination.

14. Therefore, a person may not be vaccinated until he or she has been tested for tolerance to each of the components of the vaccine with respect to allergic compatibility and the tolerance to all components of the Comirnaty vaccine has been medically confirmed.

15. Until then, vaccination with the Comirnaty vaccine must be prohibited due to the possibility of a serious health hazard.

16. An infringement not only violates the aforementioned provisions of the Medicinal Products of the Medicines Act, but also other principles of general criminal law.

17. All statements also apply to the vaccine Spikevax from MODERNA!

Heidelberg, 27 December 2021

Beate Bahner[signed]

3

Source: shortXXvids

Keywords

Bahner, Beate Bahner, BioNTech, Cominarty, EMA, European Medicines Agency, germany, imprisonment, Legal Opinion, Pfizer, prison, punishment

Back to All Cases